668270-11-9

Basic information

• Product Name: Linagliptin iMpurity G
• Synonyms: (S)-8-(3-aMinopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-Methyl-1-((4-Methylquinazolin-2-yl)Methyl)-1H-purine-2,6(3H,7H)-dione;Linagliptin iMpurity G;S-Linagliptin;(S)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-1H-purine-2,6-dione;8-[(3S)-3-Amino-1-piperidinyl]-7-(2-butyn-1-yl)-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-3,7-dihydro-1H-purine-2,6-dione;Linagliptin Impurity 10 (S-Isomer);Linagliptin Impurity 10
• CAS NO: 668270-11-9
• Molecular Formula: C25H28N8O2
• Molecular Weight: 472.54222
• Mol File: 668270-11-9.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 661.2±65.0 °C(Predicted)
• Appearance: /
• Density: 1.39±0.1 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• PKA: 10.01±0.20(Predicted)
• CAS DataBase Reference: Linagliptin iMpurity G(CAS DataBase Reference)
• NIST Chemistry Reference: Linagliptin iMpurity G(668270-11-9)
• EPA Substance Registry System: Linagliptin iMpurity G(668270-11-9)

Safety Data

• Hazardous Substances Data: 668270-11-9(Hazardous Substances Data)

Usage

Description

Linagliptin iMpurity G is a synthetically derived impurity of Linagliptin, a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor. It is used in the pharmaceutical industry for quality control and assurance purposes, ensuring the purity and efficacy of Linagliptin as a medication for type 2 diabetes treatment.

Uses

Used in Pharmaceutical Industry:
Linagliptin iMpurity G is used as a reference compound for quality control and assurance in the production of Linagliptin. It helps in monitoring the purity and consistency of the active pharmaceutical ingredient (API) Linagliptin, ensuring the safety and efficacy of the final drug product for the treatment of type 2 diabetes.
Additionally, Linagliptin iMpurity G may be utilized in research and development for the investigation of potential side effects or interactions with Linagliptin, further enhancing the understanding of its therapeutic profile and safety profile.

Relevant articles and documents

8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS MEDICAMENTS

The invention relates to substituted xanthines of general formula (I) wherein R1 to R3 have the designations cited in patent claims 1 to 16, and to the tautomers, stereoisomers, mixtures, prodrugs and salts thereof, which have precio